Biogen Inc.
Biogen
BIIB · NASDAQ
Healthcare
Catalog as of September 15, 2026. Not a live market feed.
- Fiscal Year
- 2025
- Revenue
- $9.9B
- Assets
- $29.4B
- SEC filing
- DEF 14A
- Filed
- April 28, 2026
Executive Compensation
Compensation reported for Biogen’s named executive officers, including salary, stock awards, incentive compensation, other compensation, and total compensation.
Christopher A. Viehbacher
President And Chief Executive Officer
$23.6M
Reported total
- Salary
- $1,727,885
- Stock awards
- $18,368,875
- Incentives
- $3,190,875
- Option awards
- $0
- Other
- $358,369
Susan H. Alexander
Executive Vice President, Chief Legal Officer
$8.1M
Reported total
- Salary
- $1,028,111
- Stock awards
- $5,845,129
- Incentives
- $1,062,219
- Option awards
- $0
- Other
- $197,058
Nicole C. Murphy
Head Of Pharmaceutical Operations And Technology
$7.6M
Reported total
- Salary
- $909,109
- Stock awards
- $5,566,081
- Incentives
- $977,828
- Option awards
- $0
- Other
- $122,487
Priya A. Singhal
Head Of Development
$7.6M
Reported total
- Salary
- $929,712
- Stock awards
- $5,566,081
- Incentives
- $951,731
- Option awards
- $0
- Other
- $123,863
Robin C. Kramer
Executive Vice President And Chief Financial Officer
$5.8M
Reported total
- Salary
- $759,617
- Stock awards
- $4,173,781
- Incentives
- $788,252
- Option awards
- $0
- Other
- $84,934
Michael R. McDonnell
Former Executive Vice President And Chief Financial Officer
$271K
Reported total
- Salary
- $226,895
- Stock awards
- $0
- Incentives
- $0
- Option awards
- $0
- Other
- $43,955
Christopher A. Viehbacher
President And Chief Executive Officer
$23.6M
Reported total · FY2025 · SCT Total as filed
Source: DEF 14A Summary Compensation Table, filed April 28, 2026.
- Salary
- $1.7M
- Stock Awards
- $18.4M
- Incentives
- $3.2M
- Other
- $358K
Historical Compensation
Christopher A. Viehbacher total compensation, fiscal years 2023–2025.
| Fiscal Year | Salary | Stock Awards | Total Compensation |
|---|---|---|---|
| 2025 | $1,727,885 | $18,368,875 | $23,646,004 |
| 2024 | $1,600,000 | $18,010,911 | $24,166,665 |
| 2023 | $1,600,000 | $0 | $4,069,913 |
Named Executive Officers
Christopher A. Viehbacher
President And Chief Executive Officer
Biogen · BIIB
$23.6M
FY 2025 · DEF 14A
Robin C. Kramer
Executive Vice President And Chief Financial Officer
Biogen · BIIB
$5.8M
FY 2025 · DEF 14A
Susan H. Alexander
Executive Vice President, Chief Legal Officer
Biogen · BIIB
$8.1M
FY 2025 · DEF 14A
Priya A. Singhal
Head Of Development
Biogen · BIIB
$7.6M
FY 2025 · DEF 14A
Nicole C. Murphy
Head Of Pharmaceutical Operations And Technology
Biogen · BIIB
$7.6M
FY 2025 · DEF 14A
Michael R. McDonnell
Former Executive Vice President And Chief Financial Officer
Biogen · BIIB
$271K
FY 2025 · DEF 14A
Source information
- Company
- Biogen Inc.
- Ticker
- BIIB · NASDAQ
- Filing type
- DEF 14A
- Fiscal year
- 2025
- Filing date
- April 28, 2026
- SEC accession number
- 0001193125-26-187303
Source: U.S. Securities and Exchange Commission, DEF 14A Summary Compensation Table. View SEC filing
Related Companies
Johnson & Johnson
JNJ · NYSE
Joaquin Duato
Chairman/CEO
$32.8M
FY 2025 reported total
View company →
UnitedHealth
UnitedHealth Group Incorporated
UNH · NYSE
Stephen Hemsley
Chief Executive Officer
$60.9M
FY 2025 reported total
View company →
AbbVie
AbbVie Inc.
ABBV · NYSE
Robert A. Michael
Chairman Of The Board And Chief Executive Officer
$32.5M
FY 2025 reported total
View company →
Abbott
Abbott Laboratories
ABT · NYSE
Robert B. Ford
Chairman Of The Board And Chief Executive Officer
$24.2M
FY 2025 reported total
View company →